Clinical Trial Goal
To find out:
- The highest dose of CIML-NK cells that's safe to give in combination with IL-2
- If CIML-NK cells and IL-2 are safe and work well to prevent relapse of AML or MDS
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following that's at a high risk for relapse. Your doctor can tell you this:
- AML
- Chronic myelomonocytic leukemia (CMML)
- MDS
- MDS/myeloproliferative neoplasm (MPN)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
CIML-NK cells are a type of allogeneic (cells from a donor) immune cell that doctors think will attack and kill cancer cells.
IL-2 is a drug that helps your immune system work better.
You’ll get the following after BMT:
IL-2 is a drug that helps your immune system work better.
You’ll get the following after BMT:
- CIML-NK cells – Given as an intravenous (IV) infusion 1 time. The dose you'll get depends on when you start the trial and how safe it has been
- IL-2 – Given as a shot under your skin 1 time each day for 5 days
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for 1 year.
The Food and Drug Administration (FDA) has not yet approved CIML-NK cells. IL-2 has been FDA approved for the treatment of some cancers. Using it in combination with CIML-NK cells to prevent relapse of AML or MDS is new and unproven.
The Food and Drug Administration (FDA) has not yet approved CIML-NK cells. IL-2 has been FDA approved for the treatment of some cancers. Using it in combination with CIML-NK cells to prevent relapse of AML or MDS is new and unproven.
Locations
Brigham and Women's HospitalNOT_YET_RECRUITING
Boston, Massachusetts
Roman Shapiro, MD, 617-632-3470, roman_shapiro@dfci.harvard.edu
Dana-Farber Cancer InstituteRECRUITING
Boston, Massachusetts
Roman Shapiro, MD, 617-632-3470, roman_shapiro@dfci.harvard.edu
Sponsors
lead: Dana-Farber Cancer Institute
